Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 14
2013 21
2014 26
2015 40
2016 45
2017 46
2018 42
2019 28
2020 14
2021 15
2022 8
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29916799

255 results

Results by year

Filters applied: . Clear all
Page 1
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, Murakami E, Kawaoka T, Tsuge M, Aikata H, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, Chayama K. Kosaka K, et al. J Viral Hepat. 2015 Feb;22(2):158-65. doi: 10.1111/jvh.12271. Epub 2014 Jun 19. J Viral Hepat. 2015. PMID: 24943406 Clinical Trial.
Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang JH, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Iio E, et al. J Gastroenterol. 2017 Jan;52(1):94-103. doi: 10.1007/s00535-016-1225-x. Epub 2016 May 28. J Gastroenterol. 2017. PMID: 27236547 Clinical Trial.
Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K. Osawa M, et al. J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14. J Gen Virol. 2019. PMID: 31199224
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Yu ML, Ahn SH, Ishikawa H, Bhore R, Zhou N, Hernandez D, Mendez P, Kumada H. McPhee F, et al. Adv Ther. 2015 Jul;32(7):637-49. doi: 10.1007/s12325-015-0221-5. Epub 2015 Jul 9. Adv Ther. 2015. PMID: 26155891 Free PMC article.
Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Takaguchi K, et al. J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8. J Gastroenterol. 2019. PMID: 30848363
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Toyota J, et al. J Gastroenterol. 2017 Mar;52(3):385-395. doi: 10.1007/s00535-016-1245-6. Epub 2016 Aug 9. J Gastroenterol. 2017. PMID: 27502287 Clinical Trial.
255 results